Pretzel Therapeutics Receives UK MHRA Authorization for PX578 Phase 2 Trial in POLG-Mediated Mitochondrial Disease Pretzel Therapeutics, Inc., a clinical-stage biotechnology company developing a new class of medicines intended to restore mitochondrial function, improve cellular energetics and slow disease progression…
AHF Urges African Governments to Accelerate African Medicines Agency Treaty Ratification to Strengthen Pharmaceutical Independence AIDS Healthcare Foundation Calls for Regulatory Harmonisation to Expand Access to Affordable Medicines and Boost Local Pharmaceutical Manufacturing Across Africa AIDS Healthcare Foundation (AHF) is…
Align Technology Appoints Jennifer L. Davis as President and CEO, Succeeding Joseph Hogan in December 2026 Align Technology, Inc., a global medical device company specializing in digital orthodontics and restorative dentistry, has announced the appointment of Jennifer L. Davis as…
GT Metabolic Solutions Secures Series C Investment from J.P. Morgan Life Sciences Private Capital to Accelerate Global Expansion GT Metabolic™ Solutions, Inc., a medical technology company developing innovative surgical devices designed to improve gastrointestinal (GI) procedures, has announced a Series…
LA Times Publishing Launches Journal of Breakthroughs in Medicine & Science to Advance Global Scientific Research LA Times Publishing has announced the launch of the Journal of Breakthroughs in Medicine & Science (JBMS), a peer-reviewed, open-access scientific publication designed to…
Laxxon Medical Appoints Matthew Cascio as Vice President and Head of Business Development to Drive Strategic Partnerships Laxxon Medical has announced the appointment of Matthew Cascio as Vice President and Head of Business Development, strengthening the company’s leadership as it…
Align Technology Commits $1 Million to AAO Foundation to Support Future Orthodontic Educators Align Technology, Inc., a global medical device company specializing in digital orthodontics and restorative dentistry, has announced a new $1 million commitment to the American Association of…
PharmaEssentia to Present Preclinical Data on PEC2001 and PEC3001 Solid Tumor Immunotherapy Candidates at SITC 2026 PharmaEssentia Innovation Research Center (PIRC), a subsidiary of PharmaEssentia Corporation (TWSE: 6446), has announced two poster presentations featuring preclinical research from its internal drug…
GondolaBio Partners with Children’s Tumor Foundation to Advance Preclinical NF1 Drug Development Program GondolaBio, a clinical-stage biopharmaceutical company focused on developing innovative medicines for people living with genetic diseases, has announced a strategic partnership with the Children’s Tumor Foundation (CTF)…
Genmab Reports Positive Phase 3 RAINFOL-02 Results for Rina-S in Platinum-Resistant Ovarian Cancer Genmab A/S has announced positive topline results from the global Phase 3 RAINFOL™-02 clinical trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted antibody-drug conjugate…
Convergent Therapeutics Reports 84% PSA50 Response Rate for CONV01-α in Phase 2 Prostate Cancer Study Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation radiopharmaceuticals for cancer treatment, has announced encouraging results from Part 2 of the Phase 2 CONVERGE-01…
Immunis Wins National Academy of Medicine Grand Prize for IMM01-STEM Healthy Longevity Innovation Immunis, Inc., a clinical-stage biotechnology company developing first-in-class multi-active biologics for muscle health and healthy aging, has been awarded the Grand Prize in the National Academy of…